News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 23, 2014, 14:00 ET

Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed

 Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ)...

Jul 16, 2014, 11:58 ET

Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy...

Jul 08, 2014, 07:38 ET

Boehringer Ingelheim's volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood

 Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in...

Jul 02, 2014, 09:00 ET

U.S. FDA Accepts NDA Filing for Boehringer Ingelheim's Investigational Nintedanib and Grants Priority Review Designation for the Treatment of Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

 The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound...

Jun 26, 2014, 08:02 ET

Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Jun 24, 2014, 11:47 ET

Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access...

Jun 20, 2014, 08:00 ET

Boehringer Ingelheim Initiates RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation

 Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate). The...

Jun 19, 2014, 07:59 ET

Study findings show tiotropium Respimat®* well-tolerated and effective in Japanese patients with symptomatic asthma

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat®*)5µg, a once-daily...

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...

Jun 16, 2014, 11:45 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Type 2 diabetes: Investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials

Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) were...

Jun 15, 2014, 15:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials

 Two phase III clinical trials found  the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels...

Jun 14, 2014, 13:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®

For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the...

Jun 09, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 43 Presentations at the 74th American Diabetes Association Scientific Sessions®

 More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly...

May 30, 2014, 08:00 ET

ASCO 2014: Boehringer Ingelheim to present its latest oncology research including new data for Gilotrif® (afatinib) in advanced lung cancer patients

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif® (afatinib) and investigational compounds,...

May 28, 2014, 08:00 ET

Boehringer Ingelheim Announces Comprehensive Settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) Litigation

 Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation...

May 23, 2014, 06:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe

The European Commission granted marketing authorization for Jardiance® (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2)...

May 21, 2014, 11:15 ET

Boehringer Ingelheim Presents First Phase 3 Data on Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD

 Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the...

May 18, 2014, 17:00 ET

Phase 3 INPULSIS™ Trials Published in the New England Journal of Medicine Show Investigational Nintedanib Slowed Lung Function Loss in People with Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim announced the results of its two pivotal Phase 3 INPULSIS™ trials (INPULSIS™-1 and -2; NCT01335464 and...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge